Pain management in the elderly is challenging due to the increased sensitivity to opioid adverse effects with ageing. Several studies have examined the effect of pregabalin on postoperative pain relief in middle-aged patients after noncardiac surgery, 1 -7 and pregabalin has been shown to reduce consumption of opioids after operation. 5 8 9 Pregabalin is also effective in the treatment of anxiety. 10 -12 Another gabapentinoid, gabapentin, was reported to decrease postoperative delirium in elderly surgical patients. 13 Gabapentinoids reduce the hyperexcitability of dorsal horn neurones induced by tissue injury and may potentially prevent the development of chronic pain after surgery. 6 7 14 15 On the basis of the pharmacokinetic properties of pregabalin, the risk of pharmacokinetic drug interactions is low. 16 Pregabalin is rapidly absorbed after oral dosing. It does not bind to plasma proteins and is not metabolized by the liver; it is excreted unchanged by the kidneys. At therapeutic doses, pregabalin is not metabolized by the cytochrome P450 system and thus should not affect the metabolism of drugs metabolized via this route. 17 From a theoretical point of view, pregabalin might be a relatively safe drug in elderly patients, who often require multiple pharmaceutical agents for co-morbid conditions. The primary aim of the present study was to investigate the effect of preoperative and postoperative pregabalin on the consumption of oxycodone in elderly patients undergoing cardiac surgery. Our secondary aim was to study the influence of pregabalin on postoperative confusion. Additionally, the side-effects of opioids were registered, and the incidence of postoperative pain 3 months after cardiac surgery.
Methods
Patients study. Written informed consent was obtained from all patients recruited into the study. Seventy patients, aged 75 yr or older and undergoing primary elective coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) or single valve repair or replacement with CPB, were initially included in the study. Exclusion criteria were left ventricular ejection fraction (EF) ,30%, acute renal failure or chronic renal insufficiency (plasma creatinine level .150 mmol litre 21 ), liver disease, congestive heart failure, pharmacy performed the randomization using a computergenerated randomization schedule. The pharmacy also prepared the study medication by packing pregabalin or placebo into identical capsules for blinding. Each consenting patient received the study drug according to a consecutive randomization number, which was labelled to opaque plastic containers containing the study drugs. Total parenteral oxycodone consumption before tracheal extubation and thereafter as long as the patients stayed in the ICU was recorded. Contrary to the original study protocol, total parenteral oxycodone consumption was determined during the first 16 h after extubation, because more than half of study patients were transferred to the ward earlier than 24 h after extubation. The total cumulative oxycodone consumption, orally administered oxycodone doses during the first 5 postoperative days, length of stay in the ICU, and length of hospital stay were recorded. Total consumption of ondansetron and haloperidol was recorded at the end of the care in the ICU and at the end of the fifth postoperative day. Paracetamol (Para-Tabs w 500 mg tablet, Orion Corporation, Orion Pharma, Espoo, Finland) was used for the treatment of postoperative pain at home. The VRS pain score at rest and during movement and the analgesics consumed were recorded in a telephone interview by a blinded interviewer 1 and 3 months after the surgery.
Statistical analysis
A power calculation, based on the observed oxycodone consumption in our previous study, was performed at the design stage of the study. 22 The sample size was estimated using a two-sided P level of 0.05 and a power of 0.80. A 30% (9 mg) decrease in the mean consumption of oxycodone [30 mg, standard deviation (SD) 8 mg] during the first 24 h after tracheal extubation was assumed to be clinically significant. 23 The power calculation indicated that 28 patients needed to be included in each group. To allow for a 20% drop-out rate, 35 patients were recruited into both study groups. The normality of the distribution of the data was tested with the one-sample Kolmogorov -Smirnov test. Normally distributed data are presented as means and SD and differences between the pregabalin group and study group were Opioid-sparing pregabalin tested using Student's t-test. Non-normally distributed data, MMSE, VRS, and RASS are presented as median and interquartile range. Differences in pain intensity on the VRS scores, in sedation on the RASS, and in confusion on the CAM-ICU scores between groups were analysed with Fisher's test and non-parametric data were analysed with the Mann -Whitney U-test for unpaired data. Postoperative data, the incidence of adverse effects, and the number of patients using analgesics 1 and 3 months after operation were analysed using the x 2 test. The differences in the total consumption of parental and oral oxycodone between groups were analysed using analysis of variance (ANOVA) for repeated measures, followed by one-way ANOVA and Tukey's least significant difference test. A value of P,0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Windows Version 17.0 (SPSS Ltd, Chicago, IL, USA).
Results
From April 2008 to September 2009, 233 consecutive patients undergoing CABG or valve surgery were considered for study inclusion. One hundred and sixty-three patients were excluded and 70 patients were randomized for the study (Fig. 1 ). Ten patients were excluded after initial inclusion, leaving data from 60 patients for the final analysis. Six patients in the pregabalin group were excluded from the study after randomization (Fig. 1) . One patient developed delirium the night before operation. Three patients suffered from perioperative stroke. One of these three patients had a very large intraoperative stroke, remained intubated, and died 1 month after operation. The two remaining patients with stroke were excluded from the study on the second postoperative day. One patient was excluded because of postoperative bleeding and one refused to continue the study on the third postoperative day. Four patients in the placebo group were excluded from the study (Fig. 1) . Two patients had renal failure after operation requiring renal replacement therapy, one patient needed re-intubation because of postoperative pneumonia, and one patient required prolonged intubation due to a surgical complication. One patient in the pregabalin group received naloxone for assumed opioid-induced respiratory depression (hypercarbia). Some minor violations of the study protocol occurred. These patients were not excluded from the study. However, data from the days when these patients were medicated against the study protocol were excluded from the final analysis. Three patients, one in the pregabalin group and two in the placebo group, received two doses of tramadol during the study period. Two patients were given i.v. meperidine because of shivering before extubation. Three patients, two in the pregabalin group and one in the placebo group, were undergoing CABG with CPB, but the operation was converted to be performed on the beating heart. One patient was undergoing aortic valve replacement, but one coronary artery bypass was performed. These patients were included in the final analysis, because the alterations in the surgical procedure did not significantly increase the duration of surgery, and were considered to have no impact on postoperative pain intensity. Table 1 reports patient characteristics and operative variables. Table 2 reports postoperative variables. There were no differences in patient characteristics or postoperative data between the study groups, except for the time to extubation, which was 138 min longer in the pregabalin group than in the placebo group (Tables 1 and 2 ; P,0.05). The mean MMSE scores were similar between the study groups before and after the operation. The mean preoperative MMSE scores did not differ significantly from the postoperative MMSE scores in either study group. The MMSE scores of 13 patients (43%) in the pregabalin group and of 19 patients (61%) in the placebo group decreased on the fifth postoperative day after surgery compared with preoperative values (Tables 1 and 2 ). The length of stay in the ICU and in the hospital did not differ significantly between the study groups (Table 2 ). Eighteen patients (62%) in the pregabalin group and 17 patients (55%) in the placebo group were transferred to the ward from the ICU earlier than 24 h after extubation. One patient with unstable haemodynamic status in the pregabalin group and two patients who had confusion and postoperative delirium in the placebo group stayed in the ICU for 5 postoperative days.
Consumption of oxycodone
Consumption of parenteral oxycodone before extubation was higher in the pregabalin group. However, the dose of oxycodone per hour before extubation (average 1.0 mg h 21 ) was similar in both study groups, because the time to extubation was longer in the pregabalin group than in the placebo group ( Table 2 ). The mean cumulative parenteral consumption of oxycodone during the first 16 postoperative hours after extubation was 43% lower in the pregabalin group 8 (5) mg compared with the placebo group 14 (6) mg (P,0.001). Our original primary outcome variable, mean cumulative consumption of parenteral oxycodone during the first 24 h after extubation, was 44% lower in the pregabalin group 9 (6) mg vs the placebo group 16 (7) mg (P,0.001), but more than half of the patients were transferred to the ward earlier (between 16 and 24 h after the operation). The mean cumulative total oxycodone consumption from extubation to the end of the fifth postoperative day was 48% lower in the pregabalin group 48 (28) mg compared with the placebo group 93 (44) mg (P,0.001). Cumulative consumption of oral oxycodone after extubation to the end of the fifth postoperative day was 53% lower in the pregabalin group 30 (25) mg than in the placebo group 64 (41) mg (P,0.001). Consumption of oral oxycodone was significantly lower in the pregabalin group during the first 3 postoperative days (Fig. 2) .
Postoperative pain, sedation, and confusion
In the pregabalin group, the percentage of patients requiring analgesia (VRS ≥2) during the first 16 h after extubation was significantly lower at 2, 10, and 12 h (P,0.05; Fig. 3 ). The second dose of the study drug was given on the morning of the first postoperative day, which was 8.0 (3.4) h after extubation in the pregabalin group and 8.9 (3.6) h in the placebo group (P¼0.32). The sedation scores on RASS were not significantly different between the groups, except at 2 h after extubation, when the patients in the pregabalin group were less sedated than those in the placebo group (P,0.05; Table 2 ). The CAM-ICU confusion test score was significantly reduced in the placebo group on the first day after extubation (Table 2 ; P,0.05). The number of patients who received haloperidol either in the ICU or on the ward did not differ significantly between groups (Table 2 ).
Nausea and vomiting
Eleven (34%) patients in the pregabalin group and 12 (37%) patients in the placebo group suffered from postoperative nausea during the first 16 h after extubation. Ten patients (31%) in the pregabalin group and eight patients (25%) in the placebo group vomited during the 16 h after extubation. The incidence of nausea and vomiting and the number of 
Postoperative pain 1 and 3 months after the cardiac surgery
Nine (16%) of 57 patients reported pain at rest and 34 patients (60%) reported pain during movement at 1 month after the surgery. Thirty-seven patients (65%) used paracetamol and one patient (2%) used tramadol for analgesia. VRS pain scores at rest and at movement and the number of patients using analgesics did not differ between the study groups at 1 month after operation (Table 3) . At 3 months after surgery, only one patient (2%) had pain at rest and nine patients (16%) experienced pain during movement.
Ten patients (18%) used paracetamol and one patient used tramadol for pain relief. At 3 months after surgery, patients in the placebo group experienced pain during movement significantly more often than patients in the pregabalin group (23% vs 4%, P,0.05; Table 3 ). The number of patients using analgesics was significantly higher at 1 month postoperative than at 3 months postoperative (P,0.05). The number of patients using analgesics did not differ between the study groups at 1 and 3 months after surgery (Table 3) .
Discussion
Pregabalin has been reported to have a significant postoperative opioid-sparing effect after non-cardiac surgery. 6 7 In the current study, the opioid-sparing effect of pregabalin was demonstrated in elderly patients after cardiac surgery. Pregabalin-treated patients had less confusion on the first postoperative day, although pregabalin delayed the time to extubation. Gabapentin and pregabalin have several similar pharmacological effects. However, there are some important differences. Pregabalin has a higher bioavailability and is rapidly absorbed after oral dosing. The absorption of gabapentin, on the other hand, is dose-dependent and the peak plasma concentration of gabapentin is achieved within 2-3 h. In addition to studies in which an improvement in pain management or reduction in postoperative opioid consumption was reported, there are also many studies, in which gabapentinoids were not found to be beneficial in the treatment of postoperative pain. The effect of gabapentin on postoperative pain after cardiac surgery is still unclear. In many studies, gabapentinoids have been administered only as a single dose before non-cardiac surgery. 2 4 24 Recently, a single dose of gabapentin was reported to reduce morphine consumption and postoperative pain in middle-aged patients after cardiac surgery. 25 In contrast, Rapchuk and colleagues 26 reported that preoperative gabapentin followed by postoperative dosing for 2 days did not affect postoperative pain, sleep, or opioid consumption after cardiac surgery. A single dose of 300 mg of pregabalin has been reported to decrease the consumption of morphine compared with placebo after hip arthroplasty. 27 In patients undergoing breast surgery, 75 mg of pregabalin before operation followed by 75 mg twice daily during 7 days reduced postoperative opioid use by as much as 70%. 3 The result of our study might be explained by the fact that the study drug was administered for 5 postoperative days, covering the period during which the intensity of postoperative pain is strongest. We also found a clear opioid-sparing effect of pregabalin during the first postoperative day. Postoperative confusion in patients undergoing cardiac surgery is common. It has been attributed to the effects of microemboli, hypoperfusion, and fast re-warming during CPB. 28 The use of sedatives and opioids in the postoperative period may add to the development of confusion in cardiac surgery patients. We evaluated postoperative confusion with the CAM-ICU test. 21 Our results might indicate that the opioidsparing effect of pregabalin was linked to a reduction in postoperative confusion on the first postoperative day. Postoperative pain intensity and consumption of opioids are highest during the first 3 days after cardiac surgery. 29 The optimal dosing of pregabalin for postoperative pain management is still uncertain. In earlier postoperative pain studies, the doses of pregabalin ranged from 50 to 300 mg. 2 4 Pharmacokinetic studies with pregabalin in subjects over the age of 65 have not been reported, and it is not known whether there are age-related differences in pregabalin clearance. 16 Pregabalin is considered a safe drug without problematic pharmacokinetic interactions, but it may have some significant pharmacodynamic interactions. BenMenachem 16 reported an additive effect of pregabalin with oxycodone in impairing cognition and gross motor function; the same author stated that pregabalin enhances the effects of ethanol and lorazepam. In our study, one patient in the pregabalin group required naloxone for respiratory depression after extubation in the ICU. Pregabalin can produce central nervous system-related adverse effects such as dizziness and somnolence. It is possible that the sedative effect of pregabalin delayed the time to extubation. Additionally, it has been shown that CPB does not affect the plasma concentration of administered gabapentin before operation. 30 In this study, the administration of pregabalin did not increase the length of stay in the ICU or in the hospital. The elderly patients in this study stayed in the ICU for a significantly shorter time than patients in a previous study from our hospital. 23 The results of the present study do not indicate that the patients in the pregabalin group would have been more sedated than those in the placebo group after extubation. The incidence of postoperative stroke was 4.3% (3/70). All of the patients with stroke were in the pregabalin group (the incidence of stroke 8.6%), and all three patients had bilateral carotid artery stenosis. Two of them had a history of TIA and one patient developed postoperative atrial fibrillation. Therefore, each of these patients was at an increased risk for perioperative stroke. According to the literature, the incidence of stroke after cardiac surgery varies from 1.5% to 9%. 30 -32 Thus, the stroke incidence of these high-risk elderly patients in the present study is comparable with published reports, and the higher incidence of strokes in the pregabalin group might be coincidental. Nonetheless, the observation of three strokes in the pregabalin group has to be taken seriously.
Perioperative treatment with gabapentinoids may reduce the incidence or severity of chronic postsurgical pain. 6 14 15 The incidence of poststernotomy pain varies from 11% to 56%. 33 -36 Younger age seems to be a risk factor for the development of chronic postoperative pain. 33 A recent prospective study reported that only 11% of the patients had chronic pain at 6 and 12 months after cardiac surgery. 36 The incidence of pain 3 months after the operation was 16% in our study. A possible benefit of pregabalin treatment or older age of our patients is reflected by the very low incidence (4%) of chronic pain in the pregabalin group. However, the present study was not powered to detect differences in the incidence of postoperative chronic pain. Two published case series of patients receiving pregabalin for neuropathic pain suggest a possible association between pregabalin administration and deterioration of chronic heart failure. 37 38 In these reports, patients demonstrated clinical evidence of worsening of heart failure and weight gain after pregabalin administration. We excluded patients with left ventricular failure or renal insufficiency, and in our study, no patient in the pregabalin group developed heart failure after operation.
The main limitation of our study is the relatively small number of patients included. The power analysis was based on an estimated reduction in oxycodone consumption. A significantly larger patient population would have been needed for reliable evaluation of confusion, nausea, vomiting, or the incidence of postoperative pain. The reliability of the confusion assessment might be affected by age. The CAM-ICU scale has been validated in surgical ICU patients, but not specifically in the elderly or in the Finnish language.
Pregabalin might be a beneficial adjunct in postoperative analgesia in the elderly, although it might increase the risk to respiration depression together with opioids and other sedative drugs. In the present study, the incidence of stroke was also higher in the pregabalin group, but the small number of patients warrants caution in interpreting these findings.
In conclusion, pregabalin had a significant opioid-sparing effect after operation after cardiac surgery in elderly patients. Patients in the pregabalin group had less confusion on the first postoperative day, although pregabalin increased the time to extubation. Pregabalin-treated patients had less pain in the early postoperative period and during movement at 3 months after cardiac surgery. Larger scale pharmacokinetic studies and clinical evaluation of the haemodynamic effects of gabapentinoids in the elderly are needed.
